Explore every episode of the podcast Beginner's Mind
Dive into the complete episode list for Beginner's Mind. Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.
Rows per page:
50
1–50 of 203
Title
Pub. Date
Duration
SPARK 20 - 109: Philipp Baaske, CEO of Nanotemper
24 Nov 2024
00:20:28
What does it take to lead a global biotech company tackling diseases like cancer and Alzheimer’s—and still treat every team member, from executives to production staff, as equals?
In this 20-minute highlight episode, we meet Philipp Baaske, the visionary CEO of NanoTemper. From his small Bavarian village roots to global biotech innovation, Philipp shares the leadership lessons and personal philosophies that shaped his journey.
Quotes:
(00:01:05) “Leadership is all about emotions. It’s not about you—it’s about your people. A leader is defined by their followers, and they follow because they trust and believe in you.”
(00:04:19) “Complaining is just an excuse not to work on what you can change. Focus on improving instead.”
(00:15:54) “Every month counts when fighting cancer. If we release a drug even one month earlier, we save lives.”
Curious for more? Listen to the full episode here and dive deeper into Philipp’s remarkable journey.
Timestamps:
(00:00:00) Welcome to Spark20: Innovating Leadership
(00:16:00) Fighting Cancer: The Push for Better Tools
(00:19:20) Leadership Challenges: Tough Decisions
If you’re ready to discover actionable leadership insights, hear how innovation fuels impact, and learn why values truly matter in leadership, this is your episode. Dive into Philipp’s story, and don’t miss the chance to see how he turns bold visions into real-world breakthroughs.
EP 147: DC Palter - Why Startups Face the 'Pit of Hell': The Truth About Securing Funding
17 Nov 2024
02:30:22
Startups promise innovation, but why do so many fail to secure the funding they need?
Investors demand results before committing, yet startups require resources to build. This paradox leaves founders stuck in what angel investor DC Palter calls the "pit of hell." How can startups navigate this critical gap and convince investors to bet on their vision?
🎙️ What's in the Episode: 1️⃣ Cracking the Funding Code: Learn why most pitches fail and how founders can craft stories that eliminate investor doubts and inspire confidence. 2️⃣ The Angel Investor's Playbook: Discover how to manage long-term returns and why patience is critical in high-stakes investing. 3️⃣ The Climate Tech Challenge: Explore why building billion-dollar solutions demands more than innovation—it requires grit, strategy, and understanding the full business cycle.
👤 About DC Palter: DC Palter is a seasoned venture investor, startup founder, and award-winning author. With 25 years of experience in tech, he bridges the worlds of business and storytelling. His expertise spans hard tech, climate tech, and helping startups succeed through mentorship, scrappiness, and vision.
💡 QUOTES: (01:01:19) "The best pitches show why failure isn’t just unlikely—it’s impossible."
(01:44:59) "Batteries are the key to unlocking sustainable energy solutions."
(02:15:58) "The biggest challenge is investors want a finished product, but startups need funds to build."
(01:19:52) "The best solutions don’t sell themselves; they solve real problems customers feel deeply."
(01:16:48) "The CEO’s role isn’t just building products; it’s creating a sustainable business.
⏰ Timestamps: (02:40) The Power of Storytelling in High-Stakes Business and Writing
(11:49) Bridging Science and Business: The Role of Mentorship
(17:31) Balancing Angel Investing and Flexibility
(20:42) Shifting from Corporate to Startup Mindset
(39:06) The Startup Funding "Pit of Hell"
(45:49) Why Founders Must Pitch a $100M Vision, Not Just a Great Product
(53:36) Crafting a Pitch Investors Can't Resist
(01:08:58) Understanding Hard Tech: Beyond Invention
(01:19:02) The Hard Work of Product-Market Fit
(01:42:44) Batteries: The Key to Renewable Energy
(02:05:44) The Global Privacy Paradox
(02:19:48) The Long Game of Angel Investing
If you’re ready to uncover the secrets of startup success, learn how to navigate hard tech challenges, and master the art of pitching, this episode is for you.
👀 Stay Tuned: Watch the full episode to discover the tools, strategies, and stories that can transform your approach to investing and entrepreneurship.
🔔 Subscribe, comment, and share to support the show and bring more transformative insights from leaders like DC Palter to light.
#138: The PayPal Blueprint: How Vision Without a Business Model Nearly Sunk a Tech Giant
15 Aug 2024
01:16:27
Ever wondered what it takes to build a tech giant from the ground up? Is it just about having a great idea, or is there a secret formula for success? In this episode, we dive into Jimmy Soni's The Founders, uncovering the key principles that propelled PayPal from a fledgling startup to a cornerstone of the digital economy.
In the world of investing and entrepreneurship, having a visionary idea is just the beginning. "The Founders" reveals that it’s the combination of vision, timing, and an unrelenting focus on execution that separates successful companies from the rest.
Throughout my career, I’ve learned that building a business is like solving a complex puzzle. Each piece—whether it’s hiring the right people, navigating market challenges, or building a sustainable business model—needs to fit perfectly. Drawing on my experience as an entrepreneur and investor, I’ll break down the stories and strategies from PayPal’s early days to help you understand what it really takes to create a company that lasts.
This episode dissects 10 crucial lessons from the book, each one offering valuable insights into leadership, innovation, and resilience. From taking calculated risks and building trust, to the power of culture and strategic partnerships, we’ll explore how these principles can help you build a winning team and a sustainable business.
Overwhelmed by the sheer volume of business books? This concise summary delivers the most impactful lessons from "The Founders."
Unsure how to translate entrepreneurial principles into action? We'll provide actionable takeaways and reflection questions to guide your journey.
Curious about the minds behind PayPal and its lasting impact? Gain insights into the challenges, strategies, and collaborative spirit that fueled their success.
Why Listen:
Discover the 10 Lessons for Success: Uncover the strategies that turned PayPal into a tech powerhouse.
Learn from Real-World Examples: Hear stories from the book and my own experiences that illustrate these principles in action.
Apply the Lessons to Your Own Ventures: Reflect on how you can foster innovation and build a resilient business.
Quotes:
“On the eve of its IPO, a prominent trade publication declared that the country needed PayPal ‘as much as it does an anthrax epidemic.’”
“Properly understood, PayPal’s story is a four-year odyssey of near-failure followed by near-failure.”
"PayPal started off as a product with no use case. Then we had a use case but no business model. Then we had to build a sustainable business."
"Your life will be shaped by the things you create, and the people you make them with."
Timestamps:
(00:00) Intro
(03:03) Jimmy Soni
(06:28) Overview of the Book
(10:42) Vision, Persistence, and Hiring the Right People
(17:08) Elon Musk's Bold Moves: Risk and Reward
(23:07) Peter Thiel's Contrarian Thinking: Market and Monopoly
(30:20) Max Levchin’s Obsession with Security: Building Trust
#85: Emily Mitchell - What You Need to Know About Decentralized Clinical Trials
06 Sep 2022
01:03:58
What are decentralized clinical trials?
What are the benefits of decentralized clinical trials?
Why are decentralized clinical trials the way of the future?
Emily Mitchell, Executive Director of ICON’s DCT team, discusses the benefits of these trials and what needs to be considered to ensure these benefits are realized.
Emily Mitchell has over 15 years of experience working in the CRO industry in Data Management, Project Management, and Clinical Operations. During her tenure at ICON, Emily partnered with an actigraphy vendor to run a pilot study with employees on the wear compliance and comparison of a medical grade activity tracker to a commercial grade version.
Before the pandemic, Emily helped set up and support the first fully decentralized trial at ICON. She has continued to present at various conferences around the best practices for decentralized studies, ensuring minimized patient and site burden while optimizing data capture. Emily is an active member of the Society of Clinical Data Management (SCDM) and has presented about decentralized trials at numerous conferences.
ICON is the only CRO to offer all services (without the need to contract third-party services or technology) and deliver end-to-end integrated decentralized clinical trial solutions.
ICON supported the delivery of the first decentralized clinical trial that has had positive published results in a medical journal – Nature Medicine
We are talking about
⭐ Decentralized clinical trials ⭐How they benefit patients ⭐The impact on budgeting ⭐Successful deployment of clinical trials an ⭐ Much, much more
🕛 Timestamps: (00:00) Intro (03:30) Kick off with Summer Weather (06:30) What are Decentralized Clinical Trials (DCT) (07:30) Benefits of DCT (08:45) Real-Life Example for a DCT from ICON Plc (11:48) What was the Motivation to Develop the DCT Model before the Pandemic? (14:30) Logistics in Clinical Trials (16:20) Managing DCT (17:45) Patient Response to DCT (18:35) Benefits of DCT in Increasing Diversity in Patients Population (22:30) More Diversity in Patient Population Equals More Valuable Data (26:00) The Role of Social Media in Patient Recruitment (27:22) Data Management in Decentralized Clinical Trials (29:25) Improvement in Data Collection With AI/ML, Tablets, And Wearables (31:07) DCT and associated cost (34:08) Which Indications are suitable for DCT? (37:30) How do decentralized clinical trials impact the duration of a trial? (40:15) How long does the planning phase in a DCT model take? (43:30) ICON’s Partnership Model (47:13) The Demographics of Social Media as a Recruitment Tool for Clinical Trials (50:10) Patient Experience in DCT (52:57) How to Keep Patients Motivated Through a DCT (56:00) Data Collection by Patients (57:40) Long-term follow-ups in the DCT Model (01:00:55) Patient Empowerment in Decentralized Cli
#84: Samantha Dale Strasser - Pepper Bio, MIT, And the Eco-System in Boston
29 Aug 2022
01:10:57
What is the best approach to starting a novel deep tech life science company?
In this episode, I am talking with Samatha Dale Strasser, CSO, and co-founder of Pepper Bio, about her academic career at the University of Cambridge and MIT and the process of starting Pepper Bio.
Backed by VC firm NFX, Pepper Bio uses proprietary lab methods and computational abilities to unlock a new level of sophistication in drug discovery. Called the "Google Maps for drug discovery" Pepper Bio helps partners find the safest, fastest route to new, effective drugs in clinical trials by analyzing transomics data. So far, the company has already identified applications of its technology for rare diseases in oncology, neurology, and inflammatory.
Samantha Dale Strasser, PhD, is CSO and co-founder of Pepper Bio. Samantha co-founded Pepper Bio based on foundational work she pioneered during her PhD studies at MIT. Her development of the first trans-omic machine learning platform revolutionizes how we discover drugs and treat disease. This approach has already identified and validated previously unseen insights in inflammatory diseases and undruggable cancers. She paved the way to Pepper’s first commercial partner, eager to apply this approach to central nervous system diseases.
We are talking about: ⭐The Eco-Systems in Boston ⭐ The Importance of Aligning Vision – Mission – Goals – Actions ⭐ Challenges in Drug Development ⭐ Fundraising strategies for the United States ⭐The Story Behind Pepper Bio ⭐ And Much, Much more
🕛 Timestamps: (00:00) Introduction Pepper Bio and Samantha Dale Strasser (02:30) Start of the recording (03:00) Heatwaves, Paintings, and the Sky Above Boston (05:00) Culture in Boston/Cambridge and Cambridge, UK – MIT and the University of Cambridge (16:08) Samantha's Motivation to Start Pepper Bio (19:20) The Startup Eco-System in Boston, Massachusetts (21:27) The 3 Critical Key Success Factors of the Deep Tech Eco-System in Boston (24:40) Starting Points for Global Founders to Connect to the Eco-System in and around Boston (26:40) Real Life and Digital Meetings – The Best of Two Worlds (29:55) Fundraising in the United States – 3 Key Success Factors (33:17) Relationship-building with Investors and Duration of Fundraising in 2022 (31:08) The 3 Do's and Don'ts When Fundraising with US-Based Investors (44:05) Vision Statement – Pepper Bio (47:10) The Story Behind Pepper Bio's Foundation (51:12) Challenges in Drug Development to Improve Success Rates (55:49) Novel Solutions for Making Sense of Scientific Data (01:00:15) Pepper Bio's Team (01:03:30) The Importance of Aligning Vision – Goals – Actions (01:05:00) Hiring Strategy (01:05:30) Fundraising at Pepper Bio in 2022 (01:09:10) What is the Best First Step Towards Entrepreneurship?
#83: Donna LaVoie - How to Tell Your Story in 15 Slides
18 Aug 2022
01:08:21
What is the best methodology for presenting your Company to investors, industry partners, and public funding organizations?
Here is the answer:
In this episode, Donna LaVoie presents her famous “15-slides-methodology” in great detail.
Donna is a proven strategic communications leader in health and science innovation. She is a trusted advisor on strategic communications issues, especially around complex problems affecting multiple stakeholders. She brings a unique combination of public and investor relations expertise, including product launch experience.
LaVoieHealthScience was launched in 2001 after a corporate career with signature biotech companies leading strategic communications functions during tremendous growth, product and business launches, and international geographic expansion.
As an acknowledged leader in health science communications with public and investor platforms, LaVoieHealthScience is recognized as a top 30 independent healthcare agency in the US. The agency has received more than 35 awards for its client work. It is recognized by INC.5000 Hall of Fame – Fastest Growing Private Companies, Boston Business Journal’s top Massachusetts PR firms, PharmaVOICE 100, and O’Dwyers.
We are talking about: ↪️ Why 15 slides are sufficient in corporate presentations ↪️ Why you should have an Agenda slide ↪️ Why an Appendix is important ↪️ What is Better? Detail or Simplicity? ↪️ The interplay of Problem and Solution ↪️ Why the Team slide matters ↪️ Why you need to adapt the presentation to your audience ↪️ And much, much more
🕛 Timestamps: (00:00) Intro (00:45) Donna LaVoie and LaVoieHealthSciences (02:35) Content of the Episode (03:00) Review of #bio2022 in San Diego (04:04) The 15 Slides Presentation Methodology (08:42) Why is the 15 Slides Methodology Relevant for Experienced Presenters? (12:15) Why are you here – What is your ask? (14:00) Why are conventions important? (16:05) Should Presenters consider the different cultural backgrounds when preparing for presentations? (16:51) The Importance of Colours (19:33) Storytelling, Simplicity, Novelty, and Clarity – The Ingredients of Successful Pitch Decks (24:00) Industry Dilemma (24:30) What’s Your Story? – 15 Slides Topics Overview (27:45) Title Slide (31:15) Company Snapshot (32:12) The Agenda Why Creating Anticipation as a Hook Matters in Presentations .(33:00) Describing the Problem and the Solution – Why it Matters (37:15) The Market and Target Product Profile (40:00) Competitive Positioning (42:20) The Team (46:45) The Pipeline and Clinical Data (50:00) Regulatory Strategy (51:00) Manufacturing Strategy (52:35) Commercial Strategy (55:00) Financials (56:45) Summary of the Presentation (58:30) How Specific Should Deal terms be in a Pitch Presentation? (01:01:45) Ending Slide – Cultural and Diversity Considerations (01:03:00) How Much Time Should Executives Take to Prepare their Corporate Story for Fundraising? (01:05:00) How LaVoie Health Science Helps Life Science Entrepreneurs and Investors
#82: Irene Fialka - Inspiring Stories from 20 Years of Bringing Academic Innovation Into Business
27 Jul 2022
01:22:14
Happy Birthday, Inits. Today 20 years ago – July 27, 2002 – Inits – Vienna’s most important high Tech Incubation Program was created.
In this episode, I am talking with Irene Fialka, CEO of Inits. In 20 years, Inits has supported over 300 high-tech #startups with the necessary tools for a successful and sustainable market entry.
Dr. Irene Fialka is CEO of INiTS, Vienna’s University Business Incubator (UBI), supporting entrepreneurs with R&D-based business ideas serving all academic institutions in Vienna. She has a genetics/molecular biology background and has worked with deep-tech startups since 2004.
Under her leadership, INiTS was awarded three times by UBI Globalas, one of the TOP ranked UBIs in the world. INiTS’ startups have proven to be extremely successful in raising funds (12 x the average UBI-supported startup according to UBI Global) and finding strategic partners. She worked with the founders of, e.g., Apeptico, Blue Danube Robotics, Lexogen, Lithoz, Marinomed, mySugr, and many more. Marinomed is the first of over 300 companies that went public in 2019 (IPO on the Vienna Stock exchange).
In collaboration with partners such as Boehringer Ingelheim, Pfizer, and Uniqa, Dr. Fialka and her team launched the HealthHubVienna (healthhubvienna.com) in 2018, an acceleration program for international health startups to drive innovation and change in the healthcare industry in Europe.
In this episode, we are talking about:
Success Story of Inits from 2002 to 2022
Development of the Startup Eco-System in Europe
3 Major Developments of Inits in the last 20 years
I wish the team of Inits all the best for their birthday celebration. Keep up your great work – it has a huge positive impact on the startup ecosystem in Europe
🕛 Timestamps (00:00) Kick Off (03:00) Birthday Wishes (04:00) When Did Inits Start? (05:30) From 2002 to 2022 – How Did the Eco-System in Vienna Evolve? (07:40) Early Days of Life Science in Austria – Intercell in 1997, Alexander von Gabain, Werner Lanthaler, Max Birnstiel (08:25) What was Inits Starting Point in 2002? (09:20) Tech Transfer in Austria Early 2000 – The Days of the “Ausseninsitut” (12:32) Business Models of Academic StartUps and Their Challenges – from 2002 to 2022 (15:20) Impressive KPIs of Inits (19:00) Companies are About Making Revenues (21:16) Inits For Academic Startups in 2022 (26:35) Public Funding in Austria (27:32) How the Campus in St. Marx Developed since 2006 – Vienna Bio Center, Start-Up Labs, Inits. (29:45) INits Support in 2004 (31:00) Coaching, Mentoring, and Advising for Startups (32:30) The 3 Major Developments at INITS Since 2002 (38:20) INiTs StartUps In Africa (43:20) Challenges and Opportunities in the Global StartUp Eco-System (45:05) StartUp Success Stories from the Inits Universe – MySugr, Shpock, Zoho, Marinomed, Origimm, Lithos, Ecop (52:05) Consistency between Strategy and Action – Aligning Interests (55:05) 3 Avoidable Mistakes in Startups (58:52) Patience and Endurance as Ingredients For Success (01:00:05) Digital Health – Health Hub Vienna (01:01:50) Inits Vision for the Coming Two Decades (01:02:15) Diversity and Female Founders (01:03:25) Integrating Circular Economy Concepts & Sustainability (01:04:00
#81: Astrid Woollard and Christian Niedermüller - The Future of Investments in Digital Assets
25 Jul 2022
01:26:32
What is happening in all things digital assets, cryptocurrencies, NFTs, and alike? The market crashed. Is it all over now?
Investing with experts is always the best idea when investing in new areas. This episode was recorded in February 2022, and I am happy that I had the chance to speak with two experts in digital assets from Austria:
Astrid is the CIO of Smape Capital. Their slogan is: We invest beyond mission-driven tokenized economies. She is also working as an independent consultant in digitalization, digital business models, blockchain technology applications, and IP strategy
Christian Niedermüller has been 15+ years in banking/traditional finance in very challenging roles, but finally went full time into the DLT/Blockchain and digital asset universe after being 6+ years massively involved anyway.
🕛 Timestamps (00:00) Kick Off (01:07) What is Smape Capital? (04:15) The History of Digital Assets (05:05) Who is Satoshi Nakamoto (07:07) Next Generation Token (09:53) Use Cases for NFTs (12:40) What Is DAO? (14:10) Astrid Woollard’s and Christian Niedermüller’s First Steps Into the Crypto Market (21:13) The Driving Forces Behind the Digital Asset Revolution (25:10) The Bitcoin Pizza Day (26:11) The Tokenized Economy (28:02) Use Cases for the Token Economy (33:10) Useability of Tokens for Investments in Equity, Real Estate, and other Asset Classes (37:00) Unbanking the Banked, and Banking the Unbanked (40:11) Digital Assets and Inflation. (42:55) The Remittance Network – An Opportunity for Digital Assets? (46:50) Money Laundering and the Blockchain (51:27) Digital Assets in the Metaverse – Why, What, And How (54:42) NFTs in the Metaverse (56:08) How NFTs Will Change the Gaming Industry (59:00) The Availability of Capital for Digital Asset Projects (01:01:51) New Funds in the Digital Asset Eco-System (01:06:01) Why Should Family Offices and High Networth Individuals invest in Funds Rather Than Bitcoin (01:12:42) The Future of Investing in Digital Assets
#80: Alexander Belcredi and Lorenzo Corsini - How to Create An Overnight Success As An Entrepreneur
12 Jul 2022
01:34:23
It is the 80th episode on my podcast channel. In 2020 I wanted to try how podcasts can bring value to my life science business community.
One of the first speakers on the podcast was Alexander Belcredi, Phagomed. He and Co-CEO Lorenzo Corsini started their Company in 2015 and developed Alternatives to Antibiotics.; which was also the title of Episode #9 - Alternatives to Antibiotics.
In April 2020, Alexander and Lorenzo were fundraising for their Company. Two years later, they signed an acquisition deal with the german Company BioNTech.
After the acquisition, I sometimes heard on the market that Alexander and Lorenzo's success story came a bit unexpected.
That's why I asked Alexander and Lorenzo to come back to the show to highlight how entrepreneurs create unexpected results in business.
Topics we discuss in this episode:
➡️ The Decision-Making Process to Start a Company ➡️ How to Build Processes, Structures, and Teams ➡️ The Reality of Fundraising ➡️ The 5 Key Learnings of First-Time Founders ➡️ And much, much more...
#79: Jonathan Sporn - How Psychedelic Drugs Help Ease the Mental Health Burden in Society
28 Jun 2022
01:55:37
These days many sources are highlighting the shocking scale of the global mental health crisis and how this affects approx—a staggering one billion people worldwide - over one-seventh of the global population.
“Unfortunately, as harrowing and monstrous this number is”, the investor Christian Angermayer wrote in a blog post, “it is my belief this is a gross UNDER-estimate.”
Ultimately, the number of people needing mental health support is arguably all 100% of the world's population.
I invited Dr. Jonathan Sporn, CEO of Gilgamesh Pharmaceutical, to gain more insights into the unmet medical need in mental health and the promising novel psychedelic drug development sector
Jonathan Sporn MD is a Board Certified Psychiatrist, assistant professor at Columbia University, and CEO of Gilgamesh Pharmaceuticals, based in NYC, which is developing novel psychedelic-related or inspired medicines to treat mental illness.
Topics we discuss in this episode:
➡️ Global Mental Health Situation ➡️ The History of Psychedelic Drug Development ➡️ Investors in this promising area ➡️ The Background Story to the foundation of Gilgamesh Pharmaceutical and ➡️ And the Different Ingredients Needed to Structure a Novel Game-Changing Drug Development Company
🕒 Timestamps: (00:00) Introduction to Topic, Speaker, and Company (04:00) Life in New York in 2022 (07:15) The Global Mental Health Pandemic (10:39) Mass Shootings in the United States as a result of the Mental health Situation (14:05) Why is it Necessary to Develop Novel Drugs to Fight Mental Health Issues in Society (19:00) The History of Drug Development for Mental Health Patients (24:00) How Effective Are Psychedelic Drugs to Tackle Mental Health Questions? (25:05) Psychedelic Drugs in Pop Culture (26:40) What Inspired Jonathan Sporn to Dedicate His Professional Life to Advance R&D in Psychedelic Drugs (29:30) Psychedelic Drugs Help to Observe Own Behaviour (32:30) Root Causes of Mood Disorders like Maniac Depression, Bipolar Disorder (34:05) Psychedelic Drugs Enhance Neuroplasticity (36:50) From Basic Research to Drug Development in the Pharma Industry (40:10) Mental Health R&D at J&J (43:40) S-Ketamine vs. K-Ketamine – Difference and Similarities (46:35) Early-Stage Research in Big Pharma (49:00) Big Pharma and Small Biotechs (51:50) The decision to Start A New Company (57:00) Foundation of Perception Neuroscience – From Early Stage Research to Clinical Phase 2 to Exit (59:05) Atai Life Science – Continuing Development of the Compounds against Depression Supporting links: (01:00:00) Reasons for Becoming a Serial Entrepreneur After a Successful Exit Deal (01:06:00) Drug Development is Simple – Given an Experienced Drug Development Team (01:08:00) What is the unique approach of Gilgamesh Pharmaceutical? (01:10:15) Target Product Profile of Psychedelic Drugs (01:20:30) Gilgamesh Pharmaceuticals Mission and Vision (01:23:20) Patents in Psychedelic Drug Development (01:24:45) Business Model of Gilgamesh Pharmaceutical (01:29:00) Artificial Intelligence in Psychedelic Drug Development (01:33:14) Investing in the Psychedelic Drug Development Industry (01:37:22) Life Science VCs in the Psychedelic Drug Development Industry (01:39:00) Christian Angermayer, Peter Thiel, Mike Novogratz – Investors in Psychedelic Drug Development
#78: Gerda Redl - The Future of Life Science Patents
09 Jun 2022
01:29:11
Warren Buffett recommends buying companies with a great moat. Something that makes the company unique and protects the business from the competition. Patents are the best moats. Do you want to know why? Then listen to Gerda Redl.
Who is the speaker?
Dr. Gerda Redl is a patent attorney with more than 20 years of experience in the life sciences industry.
Her technical expertise is in biotechnology, biochemistry, and chemistry, including protein engineering, biologicals, small molecules, biomarkers, antibodies, alternative scaffolds, and libraries.
Before founding REDL Life Science Patent Attorneys, she held senior management positions in biotech, mid-size, and big pharma companies. She graduated as a biochemist and received her Ph.D. in microbiology from the Technical University of Vienna.
#77: Alexander Valtingojer - How to Invest in Digital Assets
01 Jun 2022
01:50:43
What is going on in the world of digital assets in 2022? In May 2010, 10,000 BTC bought 2 Pizza.
Last year in November, the same amount had a value of 600 Million dollars. A lot has evolved since 2010 in the digital asset ecosystem.
That's why I asked Alexander Valtingojer, CEO of Coinpanion, to discuss the latest development in the crypto market. This episode was recorded in January 2022.
#76: Rich Masters - How the Pandemic Changed the Conference Industry - Bio US 2022 in San Diego
22 May 2022
00:59:57
How Did the Conference Industry Change in the last two years?
Philadelphia in 2019 was the last Bio I attended in person. In March 2020, the world shut down to respond to the novel viral threat. Since then, all conferences have been digital.
What effect did this have on the conference Industry – especially the Bio US? Listen to Rich Masters, Chief Public Affairs and Marketing Officer of Bio.
As EVP for Public Affairs, Rich Masters leads integrated communications, branding, and marketing strategy for the organization, including overseeing the policy communications that support the advocacy goals across each of BIO’s sections.
What are the topics we discuss in this episode?
What are Bio and the Bio US 2022?
How Did the Conference Industry Respond to the Lockdowns?
🕒 Timestamps: (00:00) Intro (01:36) Who is Rich Masters (02:54) What is Bio? (03:30) Opening (04:30) How is The Situation in the United States with the Pandemic These Days? (05:40) How did the Pharma Industry Respond to the Global Viral Threat? (06:00) How did BIO Help Solve the Biggest Healthcare Challenge in the last 2 years? (08:33) What Is Biotechnology Innovation Organisation (BIO)? It is not only the Bio US. (12:10) How is the Availability of Capital for Biotechnology Product Development in the United States? (14:20) What Are The Bio Business Solutions and how does it help SMEs? (15:43) Is a BIO Membership for US Companies Only, Or is it Open for European and Asian Companies? (17:40) Entrepreneurship in the United States for Bio Product Development (18:24) Where are the Bio Hotspots in the US? (19:15) The Different Sides of BIO (20:15) Big Trends in Bio in 2022 (26:20) What A Convention Model Looks Like in a Post Pandemic World (31:35) Taking the Best of Two Worlds - New On-Demand Service – All Panel Discussions, Presentations, and Speeches in One Digital Space (33:35) Bio Impact in Omaha, Nebraska (36:05) Are Digital Conferences a Replacement for Real-Life Versions?
Add on Services at the Bio: (40:00) The Midway Experience in San Diego (41:00) I am Bio (42:05) Bio US Podcast – I am Bio (42:30) Good Day Bio (42:45) Bio.News
(44:25) Challenges for Conference Organizers that Came with March 2020 (41:30) How Bio Helps their Members to Overcome Challenges Ahead Especially the SMEs (55:35) Side Events at The Bio to Meet and Mingle with the Industry (58:25) Limitless - Rich Masters – See You on June 13-16 in San Diego to Celebrate the Work of Scientists
EP 137: Hampus Jakobsson - The Secret to Venture Success: Investing in People, Not Just Ideas
28 Jul 2024
02:12:16
Did you know the secret to venture success isn't just in groundbreaking ideas? It's in the people behind them. Learn how empathy and grit fuel extraordinary success in this insightful episode. Many investors fail by only chasing ideas.
Discover why focusing on the right founders can unlock revolutionary outcomes.
Join us as Hampus Jakobsson reveals how empathy and grit are the true drivers of innovation and success. Most investors miss out on potential unicorns by focusing only on concepts. What if the real key to revolutionary success lies in the unique qualities of the founders?
🎙️ What's in the Episode:
1️⃣ Empathy and Grit: Learn why these traits are essential for founders aiming to make a significant impact.
2️⃣ Market Understanding: Understand the importance of having a clear vision for the future and how it influences investment decisions.
3️⃣ Investing in Resilience: Discover why Hampus Jakobsson focuses on people who are not just smart, but incredibly resilient and unconventional.
👤 About Hampus Jakobsson:
Hampus Jakobsson is the co-founder of Pale Blue Dot, a venture capital fund focused on climate tech innovation. He believes that the future belongs to those who think differently and have the resilience to turn their unconventional ideas into reality.
(09:58) "Reading fiction builds empathy, allowing us to experience the world through others' eyes." (28:45) "Any time in life I've been the smartest person in the room, I usually try to find other rooms." (00:57:35) "The mobile industry missed innovation due to medieval-like alliances and rigid structures." (01:03:01) "Innovators and entrepreneurs drive progress; managers often stifle it by prioritizing efficiency." (01:50:49) "The greatest founders combine empathy and grit to navigate the toughest challenges."
⏰ Timestamps:
(02:00) Mastering Multiple Accents and Languages (07:00) The Power of Fiction and Top Podcast (09:49) Building empathy through fiction's diverse perspectives (11:27) Imagining the future: mind uploading and lunar economy (17:53) Authenticity vs. Performance: The Inner vs. Outer Self (21:39) Bitcoin: A Catalyst for Metaphysical Conversations about Value (27:02) Explore vs. Exploit: Balancing Algorithmic Strategies for Growth (30:57) The Burning Library: Empathy and the Destruction of Knowledge (38:15) The Turning Point: From Arts to Mobile Technology (40:44) "The Birth of the Business Card: A Humorous Tale of Entrepreneurial Resourcefulness" (43:46) Landing a Major Client by Chance (52:44) Samsung's Speed to Market Philosophy: Thriving in a Fast-Paced Tech Environment (53:41) Competing Giants: Motorola, Samsung, Sony Ericsson, and Nokia's Battle for Supremacy (57:35) Market Saturation and Innovation: What the Mobile Industry Missed (01:03:00) Steve Jobs' Philosophy: Wasting Time in a Great Way (01:09:07) Apple vs. Google: Contrasting Paths to Innovation (01:12:00) Pride and Passion: The Secret Sauce of Successful Companies (01:16:00) Building Trust and Relationships: A Venture Capitalist's Perspective (01:19:01) Finding the Right Founder-Investor Relationship (01:20:08) Investing in the Extraordinary (01:28:00) Investing in extraordinary people and their unconventional visions (01:36:00) The drive to win is essential for great entrepreneurs (01:28:00) The Us
#75: Lisa Stöger - Creating Connections Between StartUps and International Stakeholders
17 May 2022
01:10:11
Are you interested to expand your business into Asian Markets? Then this episode might be for you.
As Program Manager of the Global Incubator Network Austria (GIN), Lisa Stöger has successfully connected the Austrian startup ecosystem with the world's most innovative startup hubs for the last 4 years. With a focus on Asian markets, she supports Austrian startups in their internationalization and market entry and introduces them to relevant, international stakeholders. Since 2016, GIN, co-managed by AWS and FFG, has been the contact point for startups regarding expansion from Austria to Asia and vice versa. Over 300 startups have benefited from the customized GIN services and internationalization programs. With her interdisciplinary academic background in Politics and Economics in Vienna and York (UK), Lisa is passionate about identifying cooperation potentials between international organizations and public institutions and is eager to apply these to promote startups and boost innovation.
What are the topics we discuss in this episode?
We cover 7 different eco-systems in Europe and Asia
🕒 Timestamps: (00:00) Opening (02:18) What is GIN? (05:00) Connecting the Start-up Eco-Systems in Europe with Asia (07:05) How Did the Pandemic Change the Way People Are Doing Business in the Startup Eco-System (10:30) The Potential of the Digitalisation in Creating New Business Relationships (14:04) The Start-up Eco-System in Israel – Linking Europe with Asia (17:05) Go Global Out of the Israeli Eco-System (18:05) The Start-Up Hub in Tel Aviv (22:05) The Silicon Wadi in Israel (24:40) Availability of Venture Capital in Austria (27:00) The Availability of Venture Capital in Austria for Companies Raising Series A Rounds and Beyond (29:15) Mainland China (33:57) How to Overcome the Language Barrier in Business (38:15) Contracts – Is English Sufficient? (39:06) The Eco-System in Singapore (41:22) The Tax Rates in Singapore (42:00) Singapore – The Gateway to South-East Asia (40:30) Startups in Hong Kong (45:00) Should Startups Create Subsidiaries in foreign Eco-System to gain more credibility? (51:53) The Start-Up Eco-System in Japan (55:15) The Japanese Business Culture (56:34) South Korea and Startups (57:18) The Business Culture in South Korea (01:01:34) The Covid Strategy in South Korea (01:06:25) What is the best first step into Asian markets? (01:08:35) Why Should Startups consider an entry into Asian Markets?
#74: Mark Herschberg - Why Networking and Leadership are Important Skills for Deeptech Entrepreneurs
10 May 2022
01:20:37
Do you want to know why networking and leadership are so important to be successful in business? And why everybody, including employees, needs to learn those skills?
Then this episode is for you.
Mark is the author of The Career Toolkit, Essential Skills for Success That No One Taught You. Educated at MIT, Mark has spent his career launching and fixing new ventures at startups, Fortune 500s, and academia. He’s developed new software languages, online marketplaces, new authentication systems, and tracked criminals and terrorists on the dark web. Mark helped create the Undergraduate Practice Opportunities Program, MIT’s “Career Success Accelerator”, where he’s taught for twenty years. Mark also serves on the boards of non-profits Techie Youth and Plant a Million Corals.
➡️ Leadership ➡️ Entrepreneurship ➡️ What is Better: Alpha or Beta Leaders? ➡️ What Makes Exceptional Leaders like Elon Musk, Bill Gates or Steve Jobs? ➡️ And much much more
🕒 Timestamps: (00:00) Intro (02:00) How has life been on the East Coast in January 2022? (03:00) Travel Restriction and Mask Mandates in 2022 (05:30) Why Was it Necessary to Write “The Career Toolkit”? (07:02) The 10 Most Important Skills For Entrepreneurs (08:15) Why Are Those 10 Skills Not Taught at Universities? (11:00) What is Leadership? (13:15) Leadership and Influencers: What is the Difference in the skillset? (15:30) Is Leadership Learn- and Teachable? (17:45) Management and Leadership – What is the Difference? (20:32) Alpha Male and Beta Male – What is Better for Leadership in this Century? (23:30) Why Situational Leadership Matters (28:15) Character Traits of Exceptional Leaders Like Elon Musk, Steve Jobs, or Bill Gates (30:00) Leadership – Is it the Ceos' Job or also the duty of the Employees? (32:15) If you want to lead from the front, you must first learn to lead from behind (31:53) The Importance of Networking for Entrepreneurship (38:36) The Role of Networking for Fundraising Entrepreneurs (44:15) The Secret of Building and Maintaining Relationships (48:15) The Power of Introductions in Networking (49:43) Do Introduction Substitute the Relationship Building Phase? (51:45) Why Real Life Still Matters in Relationship Building (56:00) What Can and Cannot be done via Zoom During the Relationship Building Phase (01:02:36) The US Startup Eco-System in 2022 (01:06:30) What is the best way to approach the startup ecosystem in the US as a startup? (01:11:15) What is the US Eco-System Looking for in Startups? (01:14:30) The Big Vision – Why it Matters and Why Not (01:16:30) What is the best way to engage with the US Eco-System (01:17:40) Professional Background of Mark Herschberg and How you Can Reach Out to Him
Do you want to know how to value a company and what Julia Roberts has to do with it? Then listen to Bharat Kanodia in this episode number 73.
Valuation is one of the most difficult exercises in the startup world. How can you put a price tag on a company that doesn’t exist yet? Get help from an expert:
Bharat Kanodia has valued over 2000 businesses and signed off on assets worth $2.6 trillion in value. He has appraised unique assets like the Golden Gate Bridge, Atlanta Airport, Uber, Airbnb, Yahoo!, Brooklyn Bridge, Mirage Casino LV, among many others. Bharat is the Founder of Veristrat, a company that helps startup founders and VCs by telling them what their companies are worth. He lives in the San Francisco Bay area with his family and enjoys sailing, golfing, skiing, and horseback riding.
In this episode number 73 we are talking about:
➡️ The History of Entrepreneurship in San Francisco ➡️ Failure Culture ➡️ Julia Roberts ➡️ NFTs ➡️ And much much more...
🕒 Timestamps: (00:00) Intro Bharat Kanodia (04:00) History of Entrepreneurship in San Francisco (07:08) Failure Culture on the West Coast (08:40) The Startup Reality – 9 out of 10 attempts fail (10:10) Veristrat – Corporate Valuations (11:30) The Nature of Valuations (15:31) How to Deal With Valuations in the Startup World? (20:00) Valuating Companies on a Pitch Deck Basis (26:50) Beeple’s Everydays NFT – How to Put a Price Tag on It (32:00) The Valuation of Cryptocurrencies (35:34) How to Put a Price Tag on Early Stage Drug Development Companies (40:00) When Should Founders Start to get Professional Support for evaluating the company and their products? (43:35) How to Put a Price Tag on Landmarks like the Eiffel Tower (45:10) Life Habits of Successful Entrepreneurs (47:00) Atomic Habits (49:15) How to Reach Out to Bharat Kanodia
#72: Stefan Sandström - How to do Business in Japan
14 Apr 2022
01:06:41
Do you want to reach out to Japanese companies and universities? Then you should know what makes Japan special and different to have a smooth business experience.
Different Cultures – Different Rules and Different ways to success
Japan is the second biggest market for pharmaceuticals globally. The area is not only interesting for its sales potential; it is also a major R&D hub in Asia.
One of the best experts in Japanese business culture in the LSG2G Community is Stefan Sandström.
Stefan Sandström is a serial entrepreneur who lived his first life in Sweden and is now living his second life in Japan. Instead of entrepreneurship, he's set up a business development consultancy in Japan aiming at the biopharma industry. After 15 years in Japan and partnering with Mr. Kuboniwa (retired from Chugai, chairman of the management committee of JBA, Japan Bioindustry Association, chairman of GTB, Greater Tokyo Bio community, and an advisor for the Japan Government), we always help find the best solutions in increasing traction or finding the right partners.
We are talking about: ➡️ Japanese Martial Arts ➡️ How is daily life in Japan ➡️ Japanese Meeting Culture ➡️ The Role of Informal Meetings and ➡️ How to Negotiate Prices in Japan
Do you want to get in touch:
⏩ Stefan Sandström: https://www.linkedin.com/in/stefan-sandstr%C3%B6m-22279053/ ⏩ Manifestum AB: https://www.manifestum.com/iris-biotech-an-exemplary-performance-of-how-to-do-business-in-japan/
🕒 Timestamps: (00:00) Introduction (02:00) Kick-Off and Greetings to Yokohama (03:15) The Covid Situation in Japan January 2022 (05:13) Reasons to Move to Japan (06:20) Kendo and Japanese Martial Arts (08:12) Martial Arts and Business (12:07) What Makes the Japanese Business Culture So Unique? (18:55) Daily Life in Japan (27:30) What are the 3 most important things everybody needs to know before traveling to Japan? (30:50) How Important is it to build business relationships in Japan? (32:40) Business Background Stefan Sandström (35:53) What is the Right Way to Engage with Japanese Companies? – A Case Study (41:45) Japanese Meeting Culture – What are the differences between formal and informal meetings? (43:45) Mind not only what happens in meetings but also what doesn’t happen in meetings (45:15) What does it mean when in subsequent meetings, similar questions are asked? (48:17) How is it perceived to change meeting dates on short notice? (51:55) How to set up informal meetings in Japan (58:50) How to Negotiate the Price in Japan (01:01:00) What is the best first step in creating business relations with Japanese companies?
#71: Heike Schoen - How To Rescue Your Clinical Trial When at Risk to Fail
28 Mar 2022
01:36:44
Did you know that almost 90% of all product ideas fail in clinical trials?
Surprising to me was that lack of efficacy doesn't seem to be the main reason why clinical trials fail in the first place. Other factors are at play, and most of them are manageable risks when the right team is at work.
In this episode:
Strategic considerations for setting up a clinical trial
Inhouse vs Outsourced Clinical Study Management
Why clinical trials fail
Steps to getting your clinical trial back on track
Future trends of clinical trials
Who is the expert in the show? Heike Schön, Lumis International GmbH with more than 25 years of experience in international clinical research and drug development.
Timestamps: (00:00) Intro (02:25) Who Is Heike Schön, Lumis International and Lumis Consulting? (04:20) Topics in the Episode (04:30) Kick-Off (05:00) Background to Lumis International and Heike Schön (10:20) When is the Right Time to Start with the Planning of a Clinical Trial? (12:10) The Role of a Sponsor of a Clinical Trial (14:30) Who is Responsible for the Clinical Trial as a Sponsor? (16:55) When Should a Company Start to Implement Clinical Trial Management in the Organisation? (18:30) Funding Requirements for Clinical Trials (20:00) The Reality of Inhouse and Outhouse Clinical Trial Management (22:15) What to Think About When Planning Oversight Management (25:00) Relationship and Culture Management in Clinical Trials (27:25) Budget and Ressource Requirement for Clinical Trials (28: 45) 3 Steps to a Successful Clinical Trial (30:40) The 3 Main Reasons Why Clinical Trials Fail (33:30) Considerations for Patient Enrollment as a Key Success Factor for Clinical Trials (37:30) … and when enrolment fails, what are the steps to rescue the trial? (42:45) Do Inhouse Studies Require Rescue? (44:30) How to Rescue a Clinical Trial (48:30) Root Cause Analysis as a Starting Point to Rescue a Trial (52:25) Preventive Measures to Avoid Failure Early on (53:30) How Important is Leadership in a Clinical Trial? (56:30) The 3 Main Reasons to Stop a Clinical Trial – The Point of no Return (59:00) How are the Cost Calculated for Rescue Study Management? (01:00:15) Planning of a Clinical Trial – A Key Aspect of a Successful Trial (01:02:15) How to Plan Realistic Timelines and Numbers (01:07:15) The Role of Feasibility Studies in Clinical Trials (01:09:30) How Clinical Trial Management Evolved in the last 30 years (01:11:15) Upcoming Trends in Clinical Trial Management (01:13:15) Decentralized Clinical Trials (01:15:00) Artificial Intelligence And Big Data in Clinical Trial Management (01:17:55) The Digital Twin (01:19:15) The Human Factor and Leadership in Clinical Trial Management (01:21:10) The Patient in Clinical Trials (01:22:55) Planning and its contribution to clinical trial s
#70: Bruno Montanari - How Venture Capital Supports Science And Innovation
13 Mar 2022
01:39:48
Big corporations strive to bring new solutions to their customers to help them solve their most pressing problems.
To do so the corporation needs to be innovative. That's why companies like Apple, Google, Pfizer, and similar players want to cooperate with start-ups and scale-ups globally.
Such cooperations strive to collaborate with top startups, invest in them, and sometimes acquire them to have access to novel ideas. By innovating the big players stay competitive, secure growth, and also help keep their employees motivated and curious.
One of the best ways to foster innovation is creating Venture Capital funds. Venture funds collect capital to invest in high-risk early-stage innovative startups to help them grow.
In this episode, we talk about:
Why is Venture Capital important for Innovation in Life Science?
What is the Secret Sauce of Venture Capital?
Venture Capital Success Stories
What is the Current Situation of Venture Capital in Europe?
And much more
Who is the expert in the show?
Bruno Montanari is a Partner at Seroba. He has a background in venture capital and in investment banking, with a focus on the pharmaceutical, biotechnology, and medical device industries.
Bruno sits on the boards of STORM Therapeutics and Coave Therapeutics.
Timestamps: (00:00) Introduction (03:30) Start of the Conversation “How Venture Capital Supports Science & Innovation” (03:45) What is Venture Capital? (07:30) Why is Venture Capital Necessary? (08:35) How Capital Intensive is Drug Development in Life Science? (11:55) Why Do Research Organisation and Big Pharma Need Companies in Between the Value Chain? (17:15) How Much Capital is Needed to Bring a New Therapy to the Market? (19:10) Why do some Life Science Start-Ups Fail? (24:30) How Can Venture Capital Help to Build Europe Into a Startup Continent? (31:53) How Innovation Changes the World (32:40) The Entrepreneurship Mindset between Academia and Industry (36:45) The State of Venture Capital in Europe (39:00) Elements Needed to Develop the Life Science Industry in Europe (42:35) Why Do Life Science Companies in Europe get Listed on the NASDAQ? (49:00) The Advantages of Specialized Investors (50:50) Benefits for Family Offices and High Networth Individuals to Invest in a Venture Fund Rather than directly into early-stage startup companies (59:00) Seroba Life Sciences (01:00:40) Success Stories from the Venture Capital Life (01:06:15) What kind of Deals are VCs looking for? (01:09:15) The Importance of Gathering Information before Closing a Deal – on both sides of the negotiation table (01:14:10) How to Balance Pitching and Relationship Building (01:19:30) 2x/10x/100X – Why are these metrics important to VCs (01:23:30) Deal Closed and they lived happily ever after – How does life look like post-investment? (01:27:00) How VCs Support Their Portfolio Companies (01:31:35) Warren Buffett vs. Venture Capital – Why is an Exit Important to VCs? (01:39:00) How to Reach Out to Bruno Montanari and Seroba Life S
#69: Prof. Collin Ewald - Molecular Mechanisms of Healthy Ageing
26 Feb 2022
01:29:46
Lately, investors and researchers have published more and more information on longevity research and development.
Investors like Sergey Young or Christian Angermayer started to bet significant capital on this topic.
What is going on in this field on the research side? What are potential applications to increase the Lifespan? And when will those innovations hit the market?
In this episode, I had a conversation in December 2021 with Prof. Collin Ewald, ETH Zürich, about his longevity research and the future impact on the pharma industry.
In this episode, we talk about:
What is the role of the extracellular matrix during aging and longevity?
Where is currently the innovation for longevity drug discoveries done?
What aging research is going on?
The Swiss Society of Ageing and Longevity Research
And much more…
Who is the expert in the show?
Prof. Ewald is Head of the Extracellular Matrix Regeneration Laboratory, Department of Health Sciences and Technology.
Collin has a longstanding interest in the molecular biology of healthy aging and age-related pathologies.
He is the founder and currently the president of the Swiss Society for Aging Research (www.ssfar.ch). He is named under the top 1000 Longevity Leaders worldwide and the top 15 Longevity Influencers in Switzerland. He has received multiple awards, including NYAS Future Entrepreneur, recognized by the New York Academy of Sciences.
Timestamps: (00:00) Opening about the situation in Switzerland and Austria in December 2021 (05:40) Longevity, Ageing, and the Health Span (07:05) Collin Ewald – Development of Ageing Research since the 90s (10:45) What is Ageing? (16:45) What is the Possible Lifespan of Human Beings? From Stone Age to the Future (20:10) What Factors Changed in Society that helped increase the average Lifespan? (22:45) The Importance of Education on Healthy Aging (26:15) How Education and Research Evolved with the Internet (27:00) Research Focus of the Collin Ewald Lab (33:30) Doubling the Lifespan in lab trials – is it possible to translate the research into human applications? (35:40) How to Translate Research into Products with Spin Outs. (38:00) Spin Outs from the Collin Ewald Lab (47:24) The Role of Extracellular Matrix in Ageing (54:40) The Potential for Applications for Cancer Diagnostic rooted in the research of the Collin Ewald Lab (56:15) How Artificial Intelligence Helps in Research (59:45) The Challenges Longevity Drug Development Faces at the Clinical Stage (01:03:45) The Role of Food & Science in Longevity Research (01:07:45) The Swiss Society of Ageing Research & Health Policies (01:13:00) Development of Life Expectancy (01:17:20) Healthy Ageing and Social Security (01:20:25) Advice to Young People Who Want to Create Lasting Change (01:25:35) The Killer Experiment - How Failure Creates Success
BIALTEC assists animal protein producers to improve productivity and profitability through precision nutrition, understanding their particular dietary needs, analyzing them through a bioinformatics platform that uses artificial intelligence, and supplying the next generation antibiotic-free additives that will facilitate performance to obtain the desired results.
In this episode, we talk about:
The Problems in the Food Industry
What Solutions are in Development?
Bialtec’s Mission
Why You Should Create a Startup and
Much More
I hope you enjoy the conversation the same way I did.
#67: Kai Lamottke - Bringing Innovation to Life Science From China & Europe
06 Feb 2022
01:20:29
Innovation needs collaboration on a global scale. Making things happen requires entrepreneurs who love science and work day and night to connect the best minds globally and support them to translate their science into products and businesses.
In this episode, I have a conversation with Kai Lamottke, CEO and Co-Founder of Bicoll.
Dr. Kai Lamottke is co-founder & CEO of Bicoll GmbH and Bicoll Biotechnology (Shanghai) Co. Ltd., the first German-Chinese biotechnology company. His expertise and knowledge in life science and innovation sectors in China and Europe are requested by corporates, SMEs, and organizations, like European Commission. The excessive network of business, academic and political contacts allowed him to achieve business governmental grants with a value of over 23 Mio. € up to now
The Bicoll Group is a privately-owned biopharmaceutical company which includes Bicoll GmbH headquartered near Munich in Planegg / Martinsried, Germany, and its wholly-owned subsidiary Bicoll Biotechnology (Shanghai) Co. Ltd.
In this episode, we talk about
From Science to Business
Bicoll’s Mission
Finding the Business Model
How to Establish Business Between Continents
Operating in a Pandemic World
I hope you enjoy the conversation the same way I did.
EP 136: Focus and Determination: Lessons from Dan Brisse's Sports and Business Career
14 Jul 2024
01:58:52
Discover how Dan Brisse, a former X Games gold medalist, transformed his passion for snowboarding into a thriving real estate empire. In this episode of [Podcast Name], we delve deep into Dan's journey, exploring the resilience, focus, and determination that propelled him from professional sports to building Granite Towers Equity Group.
🎙️ What's in the Episode: 1️⃣ The Power of Resilience: Learn how Dan's sports background instilled a never-give-up attitude, crucial for navigating the ups and downs of real estate investing. 2️⃣ Focus and Determination: Discover the importance of unwavering focus and determination in achieving success, whether in sports or business. 3️⃣ Passion-Driven Success: Understand how Dan leveraged his passion for snowboarding to fuel his entrepreneurial journey, turning challenges into opportunities.
👨💼 About Dan Brisse: Dan Brisse is a former professional snowboarder and X Games gold medalist who transitioned into real estate investment. As the co-founder of Granite Towers Equity Group, Dan now focuses on multifamily investments and creating sustainable income streams for investors.
📌 Quotes: (00:04:15) "Creating multiple income streams through real estate transforms challenges into opportunities." (00:28:07) "Certainty comes from thousands of reps; it's like walking, not a leap of faith." (00:37:08) "Commitment means doing what's necessary without backing down, even when facing major setbacks." (01:06:32) "To win the game of business, you need to know and play by the rules." (01:36:55) "As long as we can get through the next six months with cash flow, we'll thrive."
⏰ Timestamps: (00:01:00) Discover the Secrets of Multifamily Investment Success (00:06:00) Insights on Inflation, Interest Rates, and Real Estate (00:12:02) From Passion to Profession: Dan's Snowboarding Journey (00:18:13) Hard Work and Dedication: Life of a Pro Snowboarder (00:21:11) "Overcoming Limits: The Reality of Top-Tier Snowboarding" (00:27:00) "Balancing Risk and Family: A Professional Snowboarder's Journey" (00:31:33) The Importance of Starting Early in Competitive Sports (00:35:08) Overcoming Major Setbacks to Achieve Success (00:43:15) The Importance of Defining Success for Goal Achievement (00:49:38) True Passion vs. Novelty: Differentiating Between Real and Fleeting Interest (00:52:09) Overcoming Boredom by Setting New Goals (00:56:12) Transitioning from Snowboarding to Real Estate Investing (01:06:11) Embracing Freedom in Real Estate Investment (01:12:19) The Importance of Education and Confidence in Investing (01:18:23) Real Estate Investment Strategy for Passive Income and Investor Partnership (01:23:11) Challenges and Lessons from Real Estate Investments During Volatile Markets (01:30:57) Understanding Real Estate Emotions and Market Reactions (01:36:32) Securing Cash Flow and Riding Market Cycles (01:44:28) The Discipline of Saying No in Investing (01:45:47) Learning from Pain: The Path to Successful Investing
📣 Call to Action: If you’re inspired by Dan Brisse's journey and want to learn how to harness resilience, focus, and determination for your own success, this episode is for you. Subscribe, leave a comment, and share this podcast. Your support helps us bring more insightful content to you for free.
Timestamps: (00:00) Opening Christian Soschner / Albert Missbichler (02:00) Peter Llewellyn-Davies Biotech in Austria (03:22) How was 2021 for Life Science Entrepreneurs? (05:12) How was 2021 for Biotech Austria? (06:45) The situation of Life Science Infrastructure in Austria (08:00) Lab Space in Austria (09:30) Europe Needs a Culture of Success (12:25) English Proficiency in Austria (14:08) Agenda 2022 – Biotech Austria – 3 Main Goals (16:30) Goal #4: Availability of Capital for Life Science Investments (18:10) Goal #5: Availability of Funding for Clinical Trials (19:30) Goal #6: Have Fun (20:15) Astrid Wollard / Christian Soschner / Matthias Tarasiewicz– Education – Health and Financial Literacy – Beginner’s Mindset (25:30) Why Beginner’s Mind Matters More Than Ever (28:18) The Entrepreneurial Spirit in Oxford (30:05) How Did the Start-Up Scene in Europe Evolve since the 90s? (32:25) Albert Missbichler – Entrepreneurship & Business Angel in Life Science (35:00) Fianostics – Diagnostics during Covid (37:25) From Prototype Stage to Market Entry (38:35) How Important Is Market and Financing Expertise in the Early Stages of a Company? (43:04) Entrepreneurship Mindset and Customer Needs (47:00) Outlook to 2022 – Importance of Meeting in Real Life (49:20) Direct Contact to Customers in the Digital World (52:00) Content Marketing Helps to Build Trust Online (56:30) How Building Business Relationships Changed During the Pandemic
(00:00) Christian Soschner & Stefanie Rösel – Podcast & Content Marketing (03:45) The Gary V. Content Strategy Applied at the Podcast (05:30) What Kind of Companies Can Use A Podcast for Their Marketing Purposes? (07:15) Valuations – Quo Vadis? (11:35) Macro Trends & Market Crashes (17:15) Johannes Sarx and Philipp Hainzl – How Did Life Science Evolve in the Last 10 Years in Austria – Audio Only (18:00) More than 1,000 Life Science Companies in Austria (22:35) Marinomed, Tamirna, or Valneva – Companies that started before 2008 in Austria (25:35) Expectations for 2022 – Will the Industry Move Forward at the Same Speed Like in 2020-21? (28:45) EIT Health – Co-Location Center in Vienna (30:10) In-Person Events in Austria in 2022 (33:00) Stefanie Rösel – Life Science Content Marketing & Social Media (35:35) How The Pandemic Changed The Behaviour in Business on Social Media (37:16) The Digital Presence of People and Companies Matters More Than Ever (39:45) Why Online Content Marketing Matters for B2B Companies (42:41) The Most Important Platforms for B2B Companies in 2022 (44:00) Biggest Lesson From 2021 (45:50) Outlook for 2022 – Content marketing (46:35) How Will the Transition von Web 2.0 to Web 3.0 affect Content Marketing (51:45) Julia Resch – Vienna Stoch Exchange – 250 Years (52:35) The Austrian Stock Market in 2021 – 40% Performance (53:45) The European IPO Market (54:15) Life Science and the European Stock Market (55:40) Industries on the Austrian Stock Exchange (56:35) Investment Trends from the Austrian Stock Market Perspective (57:50) Digital Assets on the Stock Markets (01:01:35) Outlook 2022 on the Stock Market (01:03:45) Matthias & Astrid - Overview over Topics from Year in Review (01:07:35) What was going on in Tech in 2021 (01:12:35) Content Marketing for Profiling
Timestamps: (02:00) Bettina Resl - Christmas Greetings (03:11) Review of 2021 - Challenges for the Healthcare System in 2021 Beyond Covid 19 (06:32) Healthy Habits are the First Step to Longevity (07:32) How Do Pharma Reach Patients? (09:12) The Importance of Health Literacy – Concept and Strategies to Improve Health Literacy for the People (16:56) What Happens to Home Office in a Post-Pandemic World (20:00) Sascha Berger – Recap of 2021 (21:45) Significant closings in the Life Science VC world during the pandemic (22:57) Lasting Effects of the Capital Flow Towards Life Science (25:20) Will the Development Speed in the Pharma Industry in 2020/21 be Lasting? (29:17) The Digital Revolution – Does it Affect the Dealflow of Life Science VCs? (31:55) Outlook for 2022 (32:25) Conference Plans for 2022 (33:29) Thomas Moser and Tilmann Buerckstuemmer – Aelian Biotechnology (35:33) Aelian Biotechnology – This was 2021 (36:00) Bit.BioDiscovery – Finding New Cell Types – The Holy Grail of Biology (37:14) Outsourcing Trend for Pharma and Biotech Companies (38:00) Trend to Digitalisation (39:38) Data – Is it More Signal or More Noise? (41:39) CRISPR - Trends (42:40) The Golden Age of Biotech (44:18) What is the Big Goal for The Holy Grail of Biology? (46:34) Golden Age of Biotech or Bubble Territory? (47:39) Increasing Health and Financial Literacy for the Common Good of Society (48:18) Data Security in Gene Editing (49:42) Paradigm Shift in Data Storage (54:38) Outlook for 2022 – Aelian Biotech (57:00) Astrid Wollard and Matthias Tarasiewicz – Recap of 2021 (58:51) Talent Shortage (01:01:15) Web 2.0 vs. Web 3.0 (01:01:55) Use-Cases in Web 3.0 Beyond Token (01:02:00) Kimberly Cornfield - Intro (01:02:30) Research Activities at the UCL in Web 3.0 and Beyond (01:04:00) European Research & Innovation at the UCL (01:05:00) Effects of the Brexit on European Collaboration with British Universities (01:07:00) How Did Collaborations between Universities Change With the Pandemic? (01:08:29) Outlook for 2022 – Focused Research Areas (01:10:20) Big Trends in Research in 2021 (01:11:00) Artificial Intelligence, Democracy, and Education (01:11:48) Astrid Woollard – Potential of Artificial Intelligence (01:13:00) Matthias Tarasiewicz – AI and Machine Lear
#60: Astrid Woollard, Dusica Lukac, Matthias Tarasiewicz, Irénée Robin - This was 2021 - A Year in Review Part 1/7
02 Jan 2022
01:14:10
This is Part 1 of the 7,5 hours conversations marathon before Christmas with speakers from previous podcast episodes and business partners of the host and co-host of the Podcast.
In this episode, we talk about
Covid19
Cryptocurrencies
Cybersecurity and
Merger & Acquisition
I hope you enjoy the conversation the same way as I did.
Dr. Sascha Berger is a Partner at TVM Capital, based in Munich, Germany. TVM Capital is one of the pioneer transatlantic Life Science Venture Capital funds with Europe and North America teams. Sascha joined TVM Capital in 2016, helped raise the current $480M fund, and works closely with entrepreneurs and founders to advance promising pharmaceutical assets, MedTech, diagnostic, and digital health technologies to the following value inflection points. Sascha is a passionate VC, a Boston Consulting Group alumnus, and has an academic chemistry and finance background.
TVM Capital is a dedicated life science venture capital firm with Europe and North America teams. Since its inception, TVM Capital has invested in entrepreneurial venture-backed companies. Over several fund generations, TVM Capital’s investment strategy has included a multi-stage investment approach spanning discovery to market-ready companies as well as profitable companies searching for growth capital. The investment focus has always been broad and includes investments in therapeutics, technology platforms, MedTech, and diagnostics.
In this episode, we talk about
How the Life Science Eco-Systems evolved in the US and Europe
TVM Capitals Investment Approach
How to reach out to VCs
And much more...
I hope you enjoy the conversation the same way as I did.
Timestamps: 00:00) Intro (02:30) The History of TVM Capital (05:45) The Development of Life Science Eco-Systems in Europe and North America (10:35) What Possibilities Do Founders Have Today to Move their Companies Forward – From the Investors Perspective (13:45) Long Term Investment Models in the Life Science Industry (17:40) Cultural Differences between North America and Europe (23:50) How to Create Companies That Become Targets for VCs (27:10) How Important is the Growth Potential of a Company for TVM? (29:05) How Much Time do VC Processes Take? (33:35) When is the Right Time to Reach out to VCs?
#58: Bettina Resl - Trends in the Pharma Industry in the 21st Century
21 Dec 2021
01:20:07
In this episode, I am having a conversation with Bettina Resl, Public Affairs Head Europe Consumer Healthcare at Sanofi.
Bettina Resl joined Sanofi Austria in May 2017 as Country Head Public Affairs & Patient Advocacy. From April 2020 to June 2021 she was also responsible for corporate communications and finally took over the position of Public Affairs Head Europe Consumer Healthcare at Sanofi on July 1, 2021.
Sanofi is dedicated to supporting people through their health challenges. Sanofi is a global biopharmaceutical company focused on human health, preventing illness with vaccines, provide innovative treatments to fight pain and ease suffering. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
In this episode, we talk about
Collaboration in the Pharmaceutical Industry
The Pharma Value Chain
The Role of Patents
And much more….
I hope you enjoy the conversation the same way I did.
Timestamps: (00:00) Introduction (03:40) Introduction Bettina Resl (04:05) What are the Duties of a Public Affairs Head Europe Consumer Healthcare at Sanofi (10:50) What Best Practices from the Development of Vaccines and Therapeutics against Sars Cov 2 can be conserved in the Pharma Industry? (14:50) Will the collaborative spirit of 2020/21 remain in the pharma industry? (17:33) Personalized Medicine (22:32) Early Stage Development Quo Vadis? (26:22) The Future Role of Big Data in Pharma and the Healthcare System (31:57) Are we at the Dawn of a New Golden Age of Biotech? (38:38) What is the Future of Early-Stage Development in Life Science in Europe? (42:00) Success Rates in Early-Stage-Development in Pharma (44:11) What is the Future of mRNA Technology? (47:49) Longevity Research – Quo Vadis? (53:25) The Future of Digitally Enhanced Healthcare Systems Entry (59:10) The Future of Diagnostics (01:03:56) Mental Health in Pharma (01:08:28) The Future of Patents in the light of a fair global distribution of vaccines and therapies (01:14:19) What are the 3 biggest bottlenecks in the pharmaceutical industry? (01:18:00) Final Question: What is the most important event or innovation in the Pharma Industry with the highest impact in the coming 10 years?
#57: Jaromír Zahrádka - Bridging Science and Business in the European Life Science Eco-System
12 Dec 2021
01:26:00
In this episode, I have a conversation with Jaromir Zahradka and we will talk about early-stage investments in DeepTech Life Science companies.
He has 5+ years of C-level experience and has been engaged in 8 Biotech spin-offs. He built a unique network within CE institutions and TTOs and has deep scientific and licensing market expertise with over 20 licensing deals worth more than USD 500m.
Jaromír was a co-founder of i&i Prague, a biotechnology incubator.
In this episode, we will talk about
Early-stage investments in a deep tech company
The complexity of spinning out technology from research organizations and
The venture capital situation in Europe
and much more
I hope you enjoy the conversation the same way I did.
#56: Ole Dammann - How to Do Clinical Research in Europe
04 Dec 2021
01:13:35
In today’s episode, we explore Clinical Development with Ole Dammann, the owner of KFGN, a group of 6 clinical trial sites in Germany, and after joining Pratia, several sites in Eastern Europe.
Ole Dammann is one of the best experts in clinical trial management in the LSG2G Community. Ole is currently working on the digitization of clinical research and the development of new business models.
In this episode, we will talk about
Business Models in the Life Science Industry
Clinical Trial Management
Changes in the Business World in the last three decades
Timestamps: (00:00) Intro (02:30) Life in Germany in October 2021 (05:50) Foundation of KFGN Group in the 90s (07:25) Extending the Clinical Network to Eastern Europe (09:10) How to Start a Collaboration During the Pandemic (12:15) How were Clinical Trials Organized in the 90s compared to today? (17:00) Clinical Trials and Big Data (19:20) The European Funding Gap for Startup and Scaleup Companies (23:20) Business Models for Clinical Trial Management in the 90s (28:35) Clinical Trials in Separate Sites – Offering New Solutions to Patients (30:40) The Effects of Personalized Medicine on the Complexity of Clinical Trial Management (35:20) Rare Diseases and the Challenges For Clinical Trial Management (38:30) Personalized Clinical Trial Management – Bring the Sites to the Patients (41:20) Effects of Wearable Technology on Clinical Trials (44:15) Wearable Technology and Data Collection for Clinical Trials (47:45) Making Science and Data Understandable and Relatable (50:00) Digital Therapeutics (52:50) Current State of Digital Therapeutics (53:40) Longevity and Clinical Trials (55:40) What Makes The Eco-System Around the Stanford University so Unique? (59:15) What is the True Sense of Business? (01:01:00) Tesla, Apple, Alphabet, Facebook, Stanford University, Palo Alto Networks – Shaping the Entrepreneurial Bay Area Mindset (01:03:15) Advantages of the European Mindset (01:05:00) What is the Right Point in Time for Early-Stage Companies to Involve Clinical Experts?
#135: Empowering Innovators: 10 Lessons from The Innovators by Walter Isaacson
04 Jul 2024
01:18:56
Ever wondered how the digital revolution came to be? Was it the work of lone geniuses, or was there something more at play? In this episode, we delve into Walter Isaacson's "The Innovators," uncovering the collaborative efforts and key principles that have shaped our technological landscape.
In the world of investing and entrepreneurship, building a multidisciplinary mental model is key to success. "The Innovators" reveals that diverse, collaborative teams have historically been the driving force behind groundbreaking solutions.
In my martial arts days, a coach taught me to study exceptional role models – a strategy akin to the famous Harvard Business Cases. Analyze success, discover core principles, then adapt them to your own unique path. After all, as Bruce Lee said, "Absorb what is useful, reject what is useless, and add what is essentially your own."
That's the lens I bring to biographies – extracting valuable lessons amidst the complexities of each individual story.
This episode dissects 10 crucial tools for fostering innovation, drawing on stories from the book and my own experiences as an entrepreneur and investor. From visionary thinking and customer-centricity to the power of persistence and collaboration, we'll explore the strategies that can help you identify winning teams and create an environment where innovation thrives.
#55: Peter Llewellyn-Davies - The Future of Life Science Entrepreneurship and Investment in Europe
25 Nov 2021
00:27:35
In this conversation, I will talk with Peter Llewellyn-Davies, CEO of Apeiron and President of Biotech Austria about the Future of Life Science Entrepreneurship and Investment in Europe.
Topics we discuss in the show:
The Development of the Life Science Eco-System in Europe
How Family Offices Support Life Science Companies in Europe
Timestamps: (00:00) Opening (01:25) How did the Life Science Ecosystem Evolve? (03:22) The Biontech Success Story (04:10) How Did The Private and Publice Sector Evolve in Europe Since 2006? (05:49) What is Biotech Austria’s Mission? (07:00) How Many Members Does Biotech Austria Have in 2021? (09:10) Biotech Success Stories From Austria (11:40) Vienna, Austria, Local Life-Science-Eco-Systems and Biontech’s Success (13:45) Why is it a Great Decision to Start a Life Science Company in Austria? (16:26) Where Do Scientists Get Follow On Funding From? (18:30) How Helpful is the New European Investment Regulation for Foreign Investors? (21:00) Fundraising Challenges for Life Science Companies (24:00) Why Life Science Investments Are Attractive (25:50) How to Get in Touch With Biotech Austria
#53: Alexander Schwartz and Ingrid Kelly Spillman - The Future of Early-Stage Deep Tech Investments in Europe
08 Nov 2021
01:34:11
In this conversation, we will talk about the future of the Early-Stage Ecosystem in Europe.
Speaker in the Episode:
Alexander Schwartz joined IST cube in 2018 as a Partner. He has more than 15 years of experience in management consulting, eight of which with McKinsey & Company.
Ingrid Kelly Spillman joined the IST Tech Transfer team in October 2018. Ingrid worked as a patent attorney in and for the pharma industry for more than a decade.
IST cube focuses on startups with a strong background in science and technology, such as academic spin-offs or young deep tech companies.
The industry gains complexity, and I am happy that a speaker from the LSG2G community has dedicated time to speak about the Future of the Food Industry.
Speaker in the Episode: Dr. Caroline E. Heil
Since Jul. 1, 2021, Caroline has been CEO of The New Meat Company AG, a young stock-listed, purpose-driven impact investment company in Berlin focusing on alternative proteins.
Caroline is intrigued by the idea of revolutionizing the food industry, especially everything animal production-related, in an environmentally friendly, healthy, and sustainable way that will allow us to feed +10 billion people in the future.
Before joining TNMC, Caroline worked for EY as a lawyer and part of the global EY Agribusiness Team.
The New Meat Co.
The firm invests in game-changing companies and founders that disrupt the status quo of the meat industry to create nutritious, tasty, and sustainable meat alternatives that are good for everyone – animals, humans, and our planet.
Topics we discuss in the show:
In this conversation, we discuss the Future Of the Food Industry and talk about topics like:
#51: Saara Inkinen - The Future of Tech Transfer in a Post-Pandemic World
22 Oct 2021
00:39:17
Tech Transfer describes the process to bring scientific inventions from the discovery stage into companies for translational and clinical R&D.
To gain more insights into this area, I invited a tech transfer expert from the LSG2G Community to this conversation.
Speaker in this Episode is Saara Inkinen, Nordic Catalyst.
Dr. Inkinen is a technology transfer and innovation management specialist based in Vienna, Austria. She originally came from Finland and had her first position in the chemical industry already in 2000.
For more details on Dr. Inkinen’s education and professional experience, please have a look at her LinkedIn profile.
Nordic Catalyst is a technology transfer and innovation management company founded by Dr. Saara Inkinen in 2018. Nordic Catalyst is located in Austria, and it works with an international client base consisting of both research organizations and companies.
Questions we discuss in the show:
What is Tech Transfer?
Why is it necessary to bring ideas from universities into startups and companies?
Is tech transfer biotech and pharma different from other tech areas?
What challenges solve tech transfer?
How has the environment changed with the pandemic?
#50: Dimitrios Tzalis - Insights Into Building CROs in Asia and in Europe
14 Oct 2021
01:56:01
In this conversation, we discuss the development of the European Pharma Eco-System, different business models, and what it takes to lead a company to success.
Today’s speaker is Dimitrios Tzalis. In the 90s, he received a Ph.D. from the University of California, San Diego, a Master of Science in Chemistry from the University of Chicago, and a Master of Science in Biochemistry from Ball State University in Muncie, Indiana USA.
1998 he returned to Germany to found Taros Chemicals GmbH & Co. KG.
Questions we discuss in the show:
When and why did Dimitrios decide to found a novel company?
How did Dimitrios find the Right Business Model?
How did the industry evolve in India and Germany over the last two decades?
How do you see the future of the life science industry globally after the push that it got with Sars Cov 2?
And more…
Timestamps: 00:00 Introduction 04:25 Introduction Dimitrios Tzalis 05:45 How to Start a Life Science Company During the Dot.com Bubble Times 08:15 The Decision to Start a Company Rather Than Applying for a Job 10:15 How did the European Life Science Eco-System Look Like in the 1990s? 12:54 Where to Get Inspiration for Writing a Business Plan? 16:54 The Structure of the Pharmaceutical Industry in the 90s/early 2000s 20:15 The Life Science Economy 22:55 The Different Mindsets to Bringing an Idea to Market 31:05 How to Fund Early-Stage Development Companies 36:30 From Founding a Company in Germany to India 41:10 How Technology Changed Collaboration in the Last Two Decades 44:25 Development of Cultural Similarities and Differences Between India and Germany Since 2000 47:00 Is there a Global Convergence of Business Culture? 52:17 The Pharma Industry in India – 2000-2021 55:20 The Future of the Pharmaceutical Industry in India 57:40 How Are Problems Approached in India vs. Europe? 01:01:20 How Entrepreneurs Approach Problems 01:03:15 Entrepreneurship & Passion 01:06:00 The Role of Passion 01:10:20 The Role of Leadership 01:12:26 Teamplay in Companies 01:14:54 Life Science Business Models 01:20:10 The Private and The Public Life Science World 01:25:00 The Future of the Life Science Industry 01:42:50 The European Culture Around Entrepreneurship 01:50:00 Short-Term Thinking and Long Term Planning 01:54:30 What is the Most Important Advice to First Time Founders
#49: Andrea Sommer - Marrying Deeptech with IP Strategy
08 Oct 2021
01:57:28
Here is my conversation with Andrea Sommer about the advantages of patents for private deep-tech companies.
Timestamps: For those who want to listen to specific parts of the episode, here are the timestamps:
00:00 Opening Christian Soschner 02:00 Intro Andrea Sommer – Importance of Patents 03:48 The Role of Patents in Deep Tech Companies – Understanding the Importance of Patent Processes 13:51 What is the right point in time to file a patent application? 15:57 Patent process in Europe 24:25 Patents – A Once in a Lifetime Event or a Process? 35:00 The importance of getting the right information for the first filing 37:10 The Reasons for an FTO Analysis from the Patent Attorney’s Perspective 41:40 When is the right time for an FTO Analysis 46:00 More Details on the Process of FTO Analysis – Better Late than Never? 51:15 How to Implement Patent and FTO Processes into the Organisation 57:27 Patent Infringement 01:02:10 Possibilities of Compulsory Licenses 01:07:15 A Brief History of Patent Laws… 01:09:20 … and The Future Of Patent Laws 01:15:00 The Future of Patents and Licenses 01:23:00 Patents and Sars CoV 2 – Would giving up patent rights by governmental enforcement tackle the right problem? 01:27:40 Tesla put all Patents into the Public Domain 2014 – Does that make sense? 01:33:20 The Role of Patents in Startups 01:40:30 Is there a difference between US Entrepreneurs and their European counterparts? 01:44:00 Perception of Entrepreneurship 01:49:00 How to Collaborate with Big Corporations as an SME 01:53:00 Patents and Investors
Timestamps: For those who want to listen to specific parts of the episode, here are the timestamps:
(00:00) Opening Christian Soschner (04:19) Introduction Joy Cürten (08:47) Introduction Kurt Höller (15:08) How Much Funding is Needed to Start an Initiative Like EIT Health (16:12) The Early Days of EIT Health (19:31) How Does EIT Operate? (21:05) Initiatives at EIT Health (26:33) Classification of Healthtech Companies (32:53) How did the pandemic shape the health tech sector in Europe? (50:00) Cultural Differences Between Entrepreneurship in the US and Europe (58:40) Development of Open Innovation and Communication in Europe (01:08:00) How the Pandemic changed the European Landscape (01:15:00) What Policy Changes Would Help the European Healthtech Sector? (01.21:00) EIC, EIT, and EIF – How The Institutions Work Together with Corporate Investors and VCs
Timestamps: For those who want to listen to specific parts of the episode, here are the timestamps:
00:00 Introduction 01:45 What is Fact and What is Fiction in Artificial Intelligence? 05:45 Artificial Intelligence in Autonomous Driving 07:30 AI in Language Translation and Understanding 11:00 AI in Education 12:20 How AI Improves Drug Discovery and Development 15:00 Analyzing Health Data under GDPR 16:55 How Wearable Technology Can Support Scientists to Get More Insights into the Development of Diseases 18:15 European North Star Projects in AI 20:45 Starting Point for SME Entrepreneurs in AI 24:00 The History of the KNOW Center 27:20 Industry Partners of the KNOW Center and Use Cases Developed with them 31:30 How Does AI Affect Labour? 34:05 Innovation Speed and AI 36:00 The Role of AI in Search 41:00 AI and Recommendation Management 43:00 Potential in Assisted Living 44:30 What is a Digital Twin? 47:35 Recommendation to SMEs to Approach KNOW Center
EP 134 - The Secret Sauce of California’s Biotech Success Revealed by Joe Panetta
22 Jun 2024
01:03:26
🚀 Discover the Secret Sauce Behind California’s Biotech Success with Joe Panetta
Unlock the keys to California’s biotech boom as we delve into the insights of Joe Panetta, President and CEO of Biocom California. In this episode, we explore the unique factors that have made California a global leader in biotech innovation. Whether you’re a CEO, investor, or biotech enthusiast, this episode offers invaluable lessons and strategies.
🎙️ What's in the Episode:
1️⃣ Convergence of Science and AI: Learn how the integration of advanced technologies is revolutionizing biotech.
2️⃣ Risk-Taking Culture: Understand the cultural elements that drive California’s unparalleled biotech success.
3️⃣ Strategic Global Collaborations: Discover how international partnerships are shaping the future of biotech in California.
👨💼 About Joe Panetta:
Joe Panetta is a pivotal figure in the biotech industry, leading Biocom California, which represents over 1,800 members. With decades of experience, Joe provides a deep dive into the strategies and innovations that have positioned California at the forefront of biotech.
Timestamps: For those who want to listen to specific parts of the episode, here are the timestamps:
00:00:00 Kick-Off 00:02:12 Intro Jama Nateqi – Give up your Freedom to gain Freedom 00:03:47 Sleeping Habit 00:04:53 Benefits of Waking Up Early 00:05:43 What Is More Important – Quality or Quantity of Sleep? 00:14:30 Why Making Your Bed Matters 00:17:31 How to Achieve Peak Performance 00:18:25 Lack of Sleep and its Impact on IQ 00:19:20 Symptoma and Working Hours 00:21:00 Meditation 00:30:00 Deep Work & Digital Drugs 00:36:00 Screentime – Modern Technology – Blessing or a Burden? 00:45:00 Does Free Will Exist? 00:53:00 Bad and Good – Yin And Yang 00:56:00 The Power of Habit 01:04:00 The Amazon Case 01:06:30 Never Stop Learning 01:08:00 The Role of Exercising 01:12:30 Health Benefits of Exercising 01:16:00 The Benefits of “Don’t Demand too Much of Yourself.” 01:20:00 New Year’s Resolutions 01:23:00 Setting Goals in the Right Size 01:26:00 The Habits of Setting Daily Goals & Time blocking 01:33:00 Attitude to Failure 01:35:00 About Nutrition 01:39:25 Why conserving willpower is crucial for deep work 01:43:00 Journaling 01:45:00 Meaning of Life & Purpose of Businesses 01:55:00 Finding the Right Team for a Vision 02:06:00 What is Your Biggest Success in Life? 02:10:00 What is the most important habit?
Timestamps: For those who want to listen to specific parts of the episode, here are the timestamps:
(0:00) Opening words (0:30) Introduction Tero Weckroth (3:00) Life Science in Finland (8:30) Life Science Investments for Business Angels (22:00) Alzheimer Drug Development and Diagnostics – Biogen and Combinostics (26:40) What is the Right Pricing for Drugs on the Market? (30:00) Availability of Capital for Early-Stage Drug Development (33:00) Importance of a Team (38:00) Public Investments and Crowdfunding (44:00) Risk Management for Investors (46:00) Differences between Privat and Public Investment and Crowdfunding (49:30) Reddit – New Development on the Stock Market (01:00:00) New Macroeconomic Era? (01:06:00) Cash, Gold, or Digital Gold? (01:15:00) Technological Evolvement in the Investment Banking World (01:20:00) Effects of the Pandemic on Regulations (01:25:00) Cryptocurrencies - Bitcoin, Cardano, Etherum & co.
Timestamps: For those who want to listen to specific parts of the episode, here are the timestamps:
(00:00) Introduction (02:23) Introduction Thomas Moser (05:45) Introduction Tilmann Bürckstümmer (08:40) Aelian Biotechnology (10:20) The Science Behind Aelian (17:50) Life Science Business Model (27:00) How to Setup Business Relationships in Life Science (34:35) Gene Editing - Why Did it Create Such a Hype? (41:00) History of Gene Editing with Insights Into CRISPR/Cas9 (45:30) Vienna - Part of The CRISPR Community (47:50) IP of CRISPR (50:00) CRISPR - Real Life Use Cases (55:05) CRISPR in Cancer Research (59:20) Are Genetically Altered Human Beings Possible? (01:04:20) Genetically Enhanced Human Beings - Reality or SciFi? (01:08:00) Gene Editing and its Role in Agriculture (01:12:00) SARS-CoV-2 - What Role Did CRISPR Play in Fighting the Pandemic? (01:12:20) CRISPR Screen for SARS-CoV-2 - Technology of Aelian Biotechnology (01:15:00) Drug Discovery for SARS-CoV-2 with CRISPR (01:18:00) Fundraising for Life Science Companies (01:27:00) Comparison of the Investment Culture in Europe and the United States (01:31:00) Major Players in the CRISPR Field (01:32:00) CRISPR - IP Landscape (01:44:00) Final Question: Advice for First Time Entrepreneurs